0
selected
-
1.
Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment.
Renzo, LD, Saraceno, R, Schipani, C, Rizzo, M, Bianchi, A, Noce, A, Esposito, M, Tiberti, S, Chimenti, S, DE Lorenzo, A
Dermatologic therapy. 2011;(4):446-51
Abstract
Tumor necrosis factor (TNF)-α is a pro-inflammatory cytokine associated with psoriasis pathogenesis. Anti-TNF-α therapies are effective in psoriasis. A significant weight gain has been reported in patients treated with anti-TNF-α agents. The aim of the present study was to evaluate the body composition changes in psoriatic patients receiving anti-TNF-α therapies according with disease phenotype. Forty patients affected with psoriasis were followed up for 24 weeks and divided into two groups: psoriasis vulgaris (PsO) and psoriatic arthritis (PsA). Anthropometric, blood biochemical, body composition parameters, resting metabolic rate, and disease activity indexes were measured at baseline and at week 24. After 24 weeks of anti-TNF-α administration, the disease activity indexes and concentration of inflammatory markers were significantly decreased. Seventy-five percent of PsO and 60% of PsA patients had an increase in body weight. Weight changes correlated with fat mass gain in the PsO group, and with fat and lean mass gain in the PsA group. In the present study, we demonstrated that a blockage of TNF-α bioactivity is related with fat and lean mass gain in both PsO and PsA subjects. The anti-TNF-α therapies could play a key role in the cross talk between adipose tissue and skeletal muscle, mediated by the reduction of TNF-α and interleukin-6 production.
-
2.
A high-fat diet temporarily accelerates gastrointestinal transit and reduces satiety in men.
Clegg, ME, Shafat, A
International journal of food sciences and nutrition. 2011;(8):857-64
Abstract
High-fat (HF) diets of 2 weeks have been shown to accelerate gastrointestinal (GI) transit and decrease satiety. However, the effects of HF diets on GI transit over longer periods than 2 weeks are unknown. We hypothesize that over 4 weeks, GI transit of a HF test meal will accelerate. The study was a repeated measures design with 10 male volunteers completing a 1-week HF diet intervention and 7 completing a 4-week HF diet intervention with testing once a week on the same day throughout the 4 weeks. Gastric emptying (GE) was measured using the (13)C-octanoic acid breath test and mouth-to-caecum transit time (MCTT) using the inulin H(2) breath test. Satiety was analysed using visual analogue scales and an ad libitum buffet meal. Body mass increased by 1.3 kg over the 4 weeks (p = 0.036). GE latency time decreased from 45 ± 8 to 41 ± 10 min (p = 0.047) over 1 week but there were no changes in any GE parameters over the 4 weeks. MCTT was accelerated over 1 week (p = 0.036) from 308 ± 43 to 248 ± 83 min. However, over the 4-week period, there was no change. Volunteers became more hungry and desire to eat became greater after 1 week (p = 0.01). Changes in satiety were also evident over the 4 weeks. Satiety was reduced in the primary weeks and then returned to baseline towards the end of the intervention. GI adaptation to a HF diet occurred over a 1-week period and returned to pre-diet levels at the end of 4 weeks.
-
3.
Effects of sucrose drinks on macronutrient intake, body weight, and mood state in overweight women over 4 weeks.
Reid, M, Hammersley, R, Duffy, M
Appetite. 2010;(1):130-6
Abstract
The long-term effects of sucrose on appetite and mood remain unclear. Normal weight subjects compensate for sucrose added blind to the diet (Reid et al., 2007). Overweight subjects, however, may differ. In a single-blind, between-subjects design, soft drinks (4x25cl per day; 1800kJ sucrose sweetened versus 67kJ aspartame sweetened) were added to the diet of overweight women (n=53, BMI 25-30, age 20-55) for 4 weeks. A 7-day food diary gave measures of total energy, carbohydrate, protein, fat, and micronutrients. Mood and hunger were measured by ten single Likert scales rated daily at 11.00, 14.00, 16.00, and 20.00. Activity levels were measured by diary and pedometer. Baseline energy intake did not differ between groups. During the first week of the intervention energy intake increased slightly in the sucrose group, but not in the aspartame group, then decreased again, so by the final week intake again did not differ from the aspartame group. Compensation was not large enough to produce significant changes in the composition of the voluntary diet. There were no effects on hunger or mood. It is concluded that overweight women do not respond adversely to sucrose added blind to the diet, but compensate for it by reducing voluntary energy intake. Alternative explanations for the correlation between sugary soft drink intake and weight gain are discussed.
-
4.
Use of polyglucosamine and physical activity to reduce body weight and dyslipidemia in moderately overweight subjects.
Cornelli, U, Belcaro, G, Cesarone, MR, Cornelli, M
Minerva cardioangiologica. 2008;(5 Suppl):71-8
Abstract
AIM: A low molecular weight chitosan (polyglucosamine, PG) was studied in overweight hyperlipemic patients under physical training. A double blind study was conducted in two groups of 30 patients (M/F; from 25 to 59 years). METHODS Tablets containing PG (2 g/day) or placebo were given for a 4-month period during a physical training (+8 MET-hours/week). Anthropometric measures, caloric intake, blood pressure, LDL and HDL cholesterol, blood glucose and triacylglycerol were measured before and after the treatment. The groups were similar for the caloric intake and expenditure and ended up with positive results in most of the parameters examined. RESULTS In PG group compared to placebo a more significant (P<0.05, t test) reduction was found for body weight (respectively 6.9+/-1.87 vs 3.0+/-1.61 kg), waist circumference (7.3+/-2.49 vs 3.1+/-4.21 cm), LDL cholesterol (44+/-14.7 vs 12.5+/-12.6 mg/dL), triacylglycerol (52+/-29.3 vs 39+/-15.2 mg/dL); HDL increase was also higher (6+/-3.6 vs and 3+/-4.2 mg/dL). At baseline metabolic syndrome (MS) according to ATP III was present in 15 and 14 patients respectively in the group PG and placebo. CONCLUSIONS Unexpectedly, at the end of the treatment MS was reduced in 12 cases of the PG group and in 3 cases only of the placebo group (P<0.05). Results indicate that PG may improve the effect of the physical training in moderately overweight patients with dyslipidemia and may be of some help in the treatment of MS.
-
5.
Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance.
Ketel, IJ, Stehouwer, CD, Serné, EH, Korsen, TJ, Hompes, PG, Smulders, YM, de Jongh, RT, Homburg, R, Lambalk, CB
The Journal of clinical endocrinology and metabolism. 2008;(9):3365-72
Abstract
CONTEXT Polycystic ovary syndrome (PCOS) and obesity are associated with diabetes and cardiovascular disease, but it is unclear to what extent PCOS contributes independently of obesity. OBJECTIVE The objective of the study was to investigate whether insulin sensitivity and insulin's effects on the microcirculation are impaired in normal-weight and obese women with PCOS. DESIGN AND POPULATION Thirty-five women with PCOS (19 normal weight and 16 obese) and 27 age- and body mass index-matched controls (14 normal weight and 13 obese) were included. Metabolic Insulin sensitivity (isoglycemic-hyperinsulinemic clamp) and microvascular insulin sensitivity [endothelium dependent (acetylcholine [ACh])] and endothelium-independent [sodium nitroprusside (SNP)] vasodilation with laser Doppler flowmetry was assessed at baseline and during hyperinsulinemia. MAIN OUTCOME MEASURES Metabolic insulin sensitivity (M/I value) and the area under the response curves to ACh and SNP curves were measured to assess microcirculatory function at baseline and during insulin infusion (microvascular insulin sensitivity). RESULTS Obese women were more insulin resistant than normal-weight women (P < 0.001), and obese PCOS women were more resistant than obese controls (P = 0.02). In contrast, normal-weight women with PCOS had similar insulin sensitivity, compared with normal-weight women without PCOS. Baseline responses to ACh showed no difference in the four groups. ACh responses during insulin infusion were significantly greater in normal-weight PCOS and controls than in obese PCOS and controls. PCOS per se had no significant influence on ACh responses during insulin infusion. During hyperinsulinemia, SNP-dependent vasodilatation did not significantly increase, compared with baseline in the four groups. CONCLUSION PCOS per se was not associated with impaired metabolic insulin sensitivity in normal-weight women but aggravates impairment of metabolic insulin sensitivity in obese women. In obese but not normal-weight women, microvascular and metabolic insulin sensitivity are decreased, independent of PCOS. Therefore, obese PCOS women in particular may be at increased risk of metabolic and cardiovascular diseases.
-
6.
Plasma leptin in men and women with seasonal affective disorder and in healthy matched controls.
Cizza, G, Romagni, P, Lotsikas, A, Lam, G, Rosenthal, NE, Chrousos, GP
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2005;(1):45-8
Abstract
Seasonal affective disorder (SAD) is a specific clinical entity characterized by recurrent episodes of depression, which typically occur during the winter with periods of remission during the spring and summer. These depression episodes are accompanied by hyperphagia with cravings for carbohydrates and moderate weight gain, and usually respond to light therapy. We examined potential relationships between leptin, a hormone known to affect appetite and weight regulation, and seasonal changes in mood and appetite by measuring plasma leptin, clinical severity of depression, appetite scores, and body mass index (BMI) in 19 women and 8 men with SAD and matched controls (20 women and 8 men) in the summer and winter. Plasma leptin was positively correlated with BMI in patients and controls during both seasons. Women and men with SAD both experienced depression in the winter, which was associated with increased appetite, caloric intake, and carbohydrate craving. Increased body weight during the winter in subjects with SAD was paralleled by a lack of concomitant changes in plasma leptin, which suggests that leptin sensitivity to changes in body weight may be influenced by seasons in subjects with SAD, similar to seasonal mammals.
-
7.
Creatine monohydrate supplementation on body weight and percent body fat.
Kutz, MR, Gunter, MJ
Journal of strength and conditioning research. 2003;(4):817-21
Abstract
Seventeen active males (age 22.9 +/- 4.9 year) participated in a study to examine the effects of creatine monohydrate supplementation on total body weight (TBW), percent body fat, body water content, and caloric intake. The TBW was measured in kilograms, percent body fat by hydrostatic weighing, body water content via bioelectrical impedance, and caloric intake by daily food log. Subjects were paired and assigned to a creatine or placebo group with a double-blind research design. Supplementation was given for 4 weeks (30 g a day for the initial 2 weeks and 15 g a day for the final 2 weeks). Subjects reported 2 days a week for supervised strength training of the lower extremity. Significant increases before and after the study were found in TBW (90.42 +/- 14.74 to 92.12 +/- 15.19 kg) and body water content (53.77 +/- 1.75 to 57.15 +/- 2.01 L) for the creatine group (p = 0.05). No significant changes were found in percent body fat or daily caloric intake in the creatine group. No significant changes were noted for the placebo group. These findings support previous research that creatine supplementation increases TBW. Mean percent body fat and caloric intake was not affected by creatine supplementation. Therefore weight gain in lieu of creatine supplementation may in part be due to water retention.
-
8.
Evidence that transient nicotine lowers the body weight set point.
Cabanac, M, Frankham, P
Physiology & behavior. 2002;(4-5):539-42
Abstract
OBJECTIVE Smokers usually gain weight when they quit smoking. The present work explores the hypothesis according to which such a rise is a behavioral response to a raised body weight set point taking place when nicotine is eliminated from the body. RESEARCH METHODS AND PROCEDURES The human body weight set point was assessed with classical behavioral and psychophysical methods, from the delay to experience negative alliesthesia when repeatedly ingesting sweet stimuli. Seven habitual smokers were tested once before lunch, after smoking (nonabstinent) as usual and once again after refraining from smoking (abstinent). Three additional nicotine-naive subjects were tested under the same procedure after receiving at 0730 h in the morning a transdermal nicotine patch (14 mg) or a placebo patch. Two of the subjects also received nicotine (7 mg) for a third session. RESULTS Oral and transdermal administration of nicotine did not decrease the initial pleasure or modify the initial palatability of eating sweet stimuli, but significantly accelerated the following onset of self-reported displeasure (negative alliesthesia) aroused by repeated ingestion of sweet stimuli. DISCUSSION These results are understood as an acute lowering of the body weight set point by nicotine. The body weight gain taking place after quitting smoking may, therefore, be explained by the removal of the lowering of the body weight set point induced by nicotine.
-
9.
Effects of creatine on isometric bench-press performance in resistance-trained humans.
Kilduff, LP, Vidakovic, P, Cooney, G, Twycross-Lewis, R, Amuna, P, Parker, M, Paul, L, Pitsiladis, YP
Medicine and science in sports and exercise. 2002;(7):1176-83
Abstract
PURPOSE The purpose of this study was to investigate the effects of creatine (Cr) supplementation on force generation during an isometric bench-press in resistance-trained men. METHODS 32 resistance-trained men were matched for peak isometric force and assigned in double-blind fashion to either a Cr or placebo group. Subjects performed an isometric bench-press test involving five maximal isometric contractions before and after 5 d of Cr (20 g.d-1 Cr + 180 g.d-1 dextrose) or placebo (200 g.d-1 dextrose). Body composition was measured before and after supplementation. Subjects completed 24-h urine collections throughout the study period; these were subsequently analyzed to provide total Cr and creatinine excretion. RESULTS The amount of Cr retained over the supplementation period was 45 +/- 18 g (mean +/- SD), with an estimated intramuscular Cr storage of 43 (13-61) mmol x kg(-1) x dry weight muscle (median [range]). Four subjects in the Cr group were classified as "nonresponders" (< or =21 mmol x kg(-1) x dry weight muscle increase following Cr supplementation) and the remaining 17 subjects were classed as "responders" (> or =32 mmol x kg(-1) x dry weight muscle). For the Cr group, peak force and total force pre- or post-supplementation were not different from placebo. However, when the analysis was confined to the responders, both the change in peak force [Repetition 2: 59(81) N vs -26(85) N; Repetition 3: 45(59) N vs -26(64) N) and the change in total force (Repetition 1: 1471(1274) N vs 209(1517) N; Repetition 2: 1575(1254) N vs 196(1413) N; Repetition 3: 1278(1245) N vs -3(1118) N; Repetition 4: 918(935) N vs -83(1095) N] post-supplementation were significantly greater compared with the placebo group (P < 0.01). For the Cr group, estimated Cr uptake was inversely correlated with training status (r = -0.68, N = 21, P = 0.001). Cr significantly increased body weight (84.1 +/- 8.6 kg pre- vs 85.3 +/- 8.3 kg post-supplementation) and fat-free mass (71.8 +/- 6.0 kg pre- vs 72.6 +/- 6.0 kg post-supplementation), with the magnitude of increase being significantly greater in the responder group than in the placebo group. CONCLUSION Five days of Cr supplementation increased body weight and fat-free body mass in resistance-trained men who were classified as responders. Peak force and total force during a repeated maximal isometric bench-press test were also significantly greater in the responders compared to the placebo group.